Wednesday, December 10, 2025, 7:00 PM – 9:00 PM CT (8:00 PM – 10:00 PM ET) | San Antonio, Texas

Cases from the Community: Investigators Discuss the Optimal Management of HER2-Positive Breast Cancer

Part 2 of a 3-Part CME Satellite Symposium Series

Register for in-person Register for webcast

 

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom H-L (Third Floor)

No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.  
 
Faculty
Professor Giuseppe Curigliano, MD, PhD
Clinical Director
Division of Early Drug Development for
Innovative Therapy
Co-Chair, Cancer Experimental
Therapeutics Program
Department of Oncology and Hemato-Oncology
University of Milano
European Institute of Oncology
Milano, Italy

Nadia Harbeck, MD, PhD
Breast Center Director
Department of Obstetrics and Gynecology
and Comprehensive Cancer Center Munich
LMU University Hospital
Munich, Germany

Ian E Krop, MD, PhD
Professor of Internal Medicine
Associate Cancer Center Director
for Clinical Research
Yale Cancer Center
New Haven, Connecticut

Nancy U Lin, MD
Associate Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Joyce O’Shaughnessy, MD
Celebrating Women Chair in
Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Dallas, Texas

Moderator
Neil Love, MD
Research To Practice
Miami, Florida



This symposium is sponsored by Research To Practice and supported by grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Puma Biotechnology Inc. This is not an official program of the San Antonio Breast Cancer Symposium® (SABCS®️).
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:00 PM — Educational Meeting

MODULE 1: Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Prof Harbeck

  • Key clinical factors affecting the selection of neoadjuvant and adjuvant systemic therapy for patients with HER2-positive localized breast cancer; effect of various therapeutic approaches on outcomes
  • Recently presented findings from the Phase III DESTINY-Breast11 study evaluating trastuzumab deruxtecan (T-DXd) as a component of neoadjuvant therapy for patients with high-risk HER2-positive localized breast cancer
  • Recently presented data from the Phase III DESTINY-Breast05 study of T-DXd versus trastuzumab emtansine (T-DM1) for patients with high-risk HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy; implications for clinical practice
  • Long-term data from the Phase III ExteNET trial of neratinib as extended adjuvant treatment for patients with HER2-positive localized breast cancer
  • Optimal integration of postadjuvant neratinib into routine practice; clinical factors guiding its use, such as hormone receptor status and extent of disease

MODULE 2: Previously Untreated HER2-Positive Metastatic Breast Cancer (mBC) — Prof Curigliano

  • Historical outcomes with standard HER2-targeted therapies for newly diagnosed HER2-positive mBC; rationale for the evaluation of effective later-line HER2-targeted treatments in the front-line setting
  • Early data with T-DXd in combination with pertuzumab as up-front therapy for HER2-positive mBC in the Phase Ib/II DESTINY-Breast07 study
  • Published efficacy and safety findings from the Phase III DESTINY-Breast09 trial documenting the benefit of T-DXd in combination with pertuzumab versus taxane/trastuzumab/pertuzumab as first-line therapy for HER2-positive mBC
  • Emerging positive findings from the Phase III HER2CLIMB-05 study assessing tucatinib versus placebo, both in combination with standard first-line maintenance therapy, after chemotherapy-based induction for HER2-positive mBC

MODULE 3: Optimal Management of Brain Metastases in Patients with HER2-Positive Breast Cancer — Dr Lin

  • Incidence of CNS metastases in patients with HER2-positive mBC and effect on overall prognosis
  • Intracranial efficacy documented with T-DXd in published research efforts, such as the DESTINY-Breast01, DESTINY-Breast02, DESTINY-Breast03 and DESTINY-Breast12 studies, the DEBBRAH trial and the TUXEDO-1 trial
  • CNS activity observed with tucatinib-based therapy in the HER2CLIMB and HER2CLIMB-02 studies
  • Optimal integration of T-DXd and tucatinib-based therapy into the management of HER2-positive mBC with CNS involvement
  • Appropriate management of disease progression that is limited to the CNS in patients with HER2-positive mBC; utility of local treatment strategies

MODULE 4: Selection and Sequencing of Therapy for Relapsed/Refractory (R/R) HER2-Positive mBC in the Absence of CNS Involvement — Dr Krop

  • Clinical, biological and practical factors influencing the selection and sequencing of therapy for patients with R/R HER2-positive mBC in the absence of CNS metastases
  • Outcomes documented among patients with previously treated HER2-positive mBC without CNS involvement in pivotal clinical research studies of T-DXd and tucatinib-based combinations
  • Long-term findings with and optimal integration of other evidence-based treatment options, such as neratinib/capecitabine, margetuximab/chemotherapy and T-DM1, into the care of patients with progressive HER2-positive mBC
  • Other promising agents and strategies under investigation for advanced HER2-positive breast cancer
  • Frequency of HER2 mutations in patients with mBC; published findings with neratinib-based therapy for this population

MODULE 5: Tolerability Considerations with HER2-Targeted Therapies — Dr O’Shaughnessy

  • Spectrum, incidence and severity of common and unique adverse events with different HER2-targeted therapies employed in the management of HER2-positive breast cancer
  • Recommended algorithms for monitoring for, mitigating and managing potentially serious toxicities documented with T-DXd, such as interstitial lung disease and left ventricular dysfunction
  • Appropriate monitoring of complete blood counts and other laboratory values during therapy with T-DXd
  • Recommended algorithms for mitigating and managing cytopenias, gastrointestinal (GI) side effects and other complications associated with T-DXd
  • Frequency, severity, prevention and optimal managementof neratinib-associated GI toxicities
  • Initial dosing of neratinib and rationale for a dose-escalation strategy with this agent

Target Audience
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appreciate the key clinical variables affecting preoperative therapy and the selection of a specific neoadjuvant regimen for patients with HER2-overexpressing localized breast cancer, and integrate this information into treatment decision-making.
  • Assess available Phase III data with HER2-directed antibody-drug conjugates as a component of neoadjuvant and adjuvant therapy for patients with high-risk localized disease, and consider the potential clinical role of this novel approach.
  • Evaluate published research data to guide the selection and duration of adjuvant and/or extended-adjuvant therapy for patients with HER2-overexpressing localized breast cancer.
  • Appraise available research data and clinical and biological factors to guide the selection of first-line therapy for patients with newly diagnosed HER2-positive metastatic breast cancer (mBC).
  • Appreciate the key clinical variables affecting the selection and sequencing of therapy for patients with relapsed/refractory HER2-positive mBC, and use this information to personalize treatment recommendations.
  • Design an optimal approach to the care of patients with HER2-positive breast cancer and CNS metastases, evaluating the implications of prior treatment exposure, symptomatology, extent of disease and other factors.
  • Recognize common and rare side effects associated with approved anti-HER2 agents, and use this information to develop supportive management plans for patients undergoing treatment for HER2-positive breast cancer.
  • Assess ongoing clinical research studies evaluating novel agents and treatment strategies under development for HER2-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof Curigliano — Advisory Committees, Consulting Agreements and Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Menarini Group, Novartis, Pfizer Inc; Data and Safety Monitoring Boards/Committees: Roche Laboratories Inc. Prof Harbeck — Consulting Agreements: Exact Sciences Corporation, Sandoz Inc, a Novartis Division; Data and Safety Monitoring Boards/Committees: Gilead Sciences Inc, IQVIA, Roche Laboratories Inc; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, Lilly, Menarini Group, MSD, Novartis, Pfizer Inc, Pierre Fabre, Roche Laboratories Inc, Stemline Therapeutics Inc, Viatris, Zuellig Pharma; Nonrelevant Financial Relationships: West German Study Group (WSG). Dr Krop — Advisory Committees: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Lilly, Seagen Inc; Consulting Agreements: ALX Oncology, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Halda Therapeutics, Novartis; Contracted Research: Pfizer Inc; Data and Safety Monitoring Boards/Committees: Novartis, Seagen Inc. Dr Lin — Consulting Agreements: Artera, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Daiichi Sankyo Inc, Eisai Inc, Janssen Biotech Inc, Menarini Group, Olema Oncology, Seagen Inc, Shorla Oncology, Stemline Therapeutics Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Merck, Olema Oncology, Pfizer Inc, Seagen Inc, Zion Pharmaceuticals; Travel: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Olema Oncology. Dr O'Shaughnessy — Advisory Committees and Consulting Agreements: Aadi Bioscience, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Daiichi Sankyo Inc, Duality Biologics, Eisai Inc, Ellipses Pharma, Exact Sciences Corporation, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, HiberCell, Jazz Pharmaceuticals Inc, Johnson & Johnson, Lilly, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Pfizer Inc, Pierre Fabre, Puma Biotechnology Inc, RayzeBio Inc, Roche Laboratories Inc, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Summit Therapeutics, Tempus, TerSera Therapeutics LLC.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Puma Biotechnology Inc.

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom H-L (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2025 San Antonio Breast Cancer Symposium is taking place.

 
This activity is intended for medical oncologists, breast surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

NOTICE
No fee is charged for this event. Please note that registration for this event is independent of registration for the San Antonio Breast Cancer Symposium.

IN-PERSON Registration
Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THIS SESSION. Our onsite registration desk will be open at 6:30 PM CT on Wednesday, December 10th. If you are interested in attending, please visit our registration desk outside the Grand Ballroom H-L (third floor) of the San Antonio Marriott Rivercenter hotel (101 Bowie St), within walking distance of the Henry B González Convention Center.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.

NOTICE:
Registration for this event is independent of registration for SABCS.
WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.